Study: Sanofi-aventis' lixisenatide improves glycemic control in people with diabetes

Results from a Phase III trial showed that people with type 2 diabetes who received sanofi-aventis' GLP-1 receptor agonist lixisenatide "significantly improved glycemic control with a pronounced postprandial effect" compared with placebo, the company reported Monday. The data, from the drugmaker's GetGoal clinical trial programme, were presented at the European Association for the Study of Diabetes meeting.
In the study, which enrolled 361 patients with type 2 diabetes who weren't currently receiving glucose-lowering therapy, subjects were randomised to receive either one of two titration regimens of lixisenatide, or placebo. Results from the 12-week trial indicated that sanofi-aventis' once-daily drug reduced A1C levels in both titration groups compared with placebo, as well as significantly reducing "the mean change from baseline two-hours postprandial glucose."
Study investigator, John Gerich, noted that "the pronounced effect on postprandial glucose control provides a rationale to investigate the combined effect of lixisenatide and long-acting insulins in patients with type 2 diabetes.”
Sanofi-aventis licensed rights to lixisenatide from Zealand Pharma.

Reference Articles
Sanofi unveils positive diabetes drug test results - (Forexyard)
Sanofi-aventis announces results of Phase III study on lixisenatide (free preview) - (The Wall Street Journal)
Investigational compound once-daily lixisenatide demonstrated significant improvement in glucose control in patients with Type 2 diabetes - (sanofi-aventis)

**Published in "First Word"